Tharimmune Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Tharimmune.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.5%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	01 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Is Hillstream BioPharma (NASDAQ:HILS) In A Good Position To Invest In Growth?

Feb 14

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:THAR - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	N/A	N/A	N/A	N/A	1
12/31/2024	N/A	N/A	N/A	N/A	1
3/31/2024	N/A	-9	-7	-7	N/A
12/31/2023	N/A	-9	-7	-7	N/A
9/30/2023	N/A	-9	-7	-7	N/A
6/30/2023	N/A	-9	-7	-7	N/A
3/31/2023	N/A	-8	-7	-7	N/A
12/31/2022	N/A	-8	-7	-7	N/A
9/30/2022	N/A	-4	-6	-6	N/A
6/30/2022	N/A	-3	-4	-4	N/A
3/31/2022	N/A	-3	-3	-3	N/A
12/31/2021	N/A	-2	-1	-1	N/A
9/30/2021	N/A	-6	-2	-2	N/A
6/30/2021	N/A	-6	-1	-1	N/A
3/31/2021	N/A	-4	-1	-1	N/A
12/31/2020	N/A	-2	-1	-1	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de THAR es superior a la tasa de ahorro (2.4%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de THAR crezcan más rápidamente que el mercado US

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de THAR crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de THAR crezcan más rápidamente que el mercado de US.

Ingresos de alto crecimiento: Se prevé que THAR no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de THAR se prevé que sea elevada dentro de 3 años.

Tharimmune Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Tharimmune, Inc. Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, Its Lead Candidate for Moderate-To-Severe Pruritus in Primary Biliary Cholangitis

Tharimmune, Inc. Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-To-Severe Pruritus in Primary Biliary Cholangitis

Tharimmune Announces 1-for-15 Reverse Stock Split, Intends to Bring it into Compliance with Nasdaq's Minimum Bid Price Requirement for Continued Listing

Tharimmune, Inc., Annual General Meeting, May 14, 2024

Tharimmune, Inc. Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate

Tharimmune, Inc. Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis

Tharimmune, Inc. Announces Initiation of Phase 1 Clinical Trial of TH104

Tharimmune, Inc. Announces Positive Topline Data with Th104, Its Lead Candidate for Moderate-To-Severe Pruritus in Chronic Liver Disease Patients

Tharimmune Reports Positive Phase 1 Data on Th104, Its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (Pbc)

Tharimmune, Inc. has completed a Follow-on Equity Offering.

Tharimmune Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

Tharimmune, Inc. has filed a Follow-on Equity Offering.

Hillstream Biopharma Progressing Towards Acquiring Clinical Stage Asset

New major risk - Shareholder dilution

Less than half of directors are independent

Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2 HER3 Solid Tumors Via Bispecific and ADC Antibodies and Biologics

Hillstream Biopharma Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Hillstream BioPharma, Inc. announced delayed 10-Q filing

Hillstream BioPharma Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Is Hillstream BioPharma (NASDAQ:HILS) In A Good Position To Invest In Growth?

Hillstream BioPharma, Inc. Announces Initial Results Evaluating the Synergy

Hillstream BioPharma, Inc. Announces Acceptance of Abstract At AACR 2023 Annual Meeting Highlighting HSB-510 as Novel Bi-Functional Inhibitor for Solid Tumors & Leukemias

Hillstream BioPharma, Inc. to Host Virtual R&D Day to Showcase Its Emerging Immuno-Oncology Pipeline Targeting Drug-Resistant Cancers

Hillstream BioPharma Receives Non-Compliance Written Notice from the Nasdaq

Hillstream BioPharma, Inc., Annual General Meeting, Aug 08, 2022

Hillstream BioPharma, Inc. (NasdaqCM:HILS) announces an Equity Buyback for $1 million worth of its shares.

Hillstream BioPharma, Inc. announced delayed annual 10-K filing

Hillstream BioPharma, Inc. has completed an IPO in the amount of $15 million.

No independent directors

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento